Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer

Woong Bae Ji, Jun Won Um, Je Seock Ryu, Kwang Dae Hong, Jung Sik Kim, Byung Wook Min, Sung Yeop Joung, Ju-Han Lee, Young Sik Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.

Original languageEnglish
Pages (from-to)2679-2682
Number of pages4
JournalAnticancer Research
Volume37
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Fluorouracil
Colorectal Neoplasms
Chemotherapy
Leucovorin
Testing
Assays
Drug Therapy
Survival
Adjuvant Chemotherapy
Bromides
Disease-Free Survival
Tumors
Survival Rate
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • 5-fluorouracil
  • Chemosensitivity
  • Chemotherapy
  • Colorectal cancer
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer. / Ji, Woong Bae; Um, Jun Won; Ryu, Je Seock; Hong, Kwang Dae; Kim, Jung Sik; Min, Byung Wook; Joung, Sung Yeop; Lee, Ju-Han; Kim, Young Sik.

In: Anticancer Research, Vol. 37, No. 5, 01.05.2017, p. 2679-2682.

Research output: Contribution to journalArticle

@article{ca40ef24ef154fdbbe5efbae044e5451,
title = "Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer",
abstract = "Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3{\%}) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.",
keywords = "5-fluorouracil, Chemosensitivity, Chemotherapy, Colorectal cancer, Survival",
author = "Ji, {Woong Bae} and Um, {Jun Won} and Ryu, {Je Seock} and Hong, {Kwang Dae} and Kim, {Jung Sik} and Min, {Byung Wook} and Joung, {Sung Yeop} and Ju-Han Lee and Kim, {Young Sik}",
year = "2017",
month = "5",
day = "1",
doi = "10.21873/anticanres.11616",
language = "English",
volume = "37",
pages = "2679--2682",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer

AU - Ji, Woong Bae

AU - Um, Jun Won

AU - Ryu, Je Seock

AU - Hong, Kwang Dae

AU - Kim, Jung Sik

AU - Min, Byung Wook

AU - Joung, Sung Yeop

AU - Lee, Ju-Han

AU - Kim, Young Sik

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.

AB - Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.

KW - 5-fluorouracil

KW - Chemosensitivity

KW - Chemotherapy

KW - Colorectal cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85019107873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019107873&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11616

DO - 10.21873/anticanres.11616

M3 - Article

VL - 37

SP - 2679

EP - 2682

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 5

ER -